Under the leadership of an aggressive opponent of anti-competitive business practices, the Federal Trade Commission is moving against drug companies and
Industry analysts are skeptical that Federal Trade Commission Chair Lina Khan can win her first fight against a drug industry merger. It will be reviewed by a judge appointed by President Donald Trump.
Industry analysts are skeptical that Federal Trade Commission Chair Lina Khan can win her first fight against a drug industry merger. It will be reviewed by a judge appointed by then-President Donald Trump.
Under the leadership of an aggressive opponent of anti-competitive business practices, the Federal Trade Commission is moving against drug companies and industry middlemen as part of the Biden administration's push for lower drug prices at the pharmacy counter.